ORIC Pharmaceuticals Reports Inducement Grantsunder Nasdaq Listing Rule 5635

ORIC Stock  USD 9.90  0.07  0.70%   
About 66% of Oric Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Oric Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Oric Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Oric Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 01, 2024 -- ORIC Pharmaceuticals, Inc. , a clinical stage oncology company...

Read at globenewswire.com
Macroaxis News: globenewswire.com
  

Oric Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Oric Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Oric Pharmaceuticals Fundamental Analysis

We analyze Oric Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oric Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oric Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Oric Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Oric Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oric Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Oric Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oric Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Oric Pharmaceuticals Related Equities

ANTXAN2 Therapeutics   21.90   
0%
100.0%
CCCCC4 Therapeutics   8.59   
0%
39.0%
CGEMCullinan Oncology   2.75   
0%
12.0%
EWTXEdgewise Therapeutics   2.48   
0%
11.0%
HOWLWerewolf Therapeutics   1.52   
0%
6.0%
PMVPPmv Pharmaceuticals   1.25   
0%
5.0%
SEERSeer   0.81   
0%
3.0%
ANEBAnebulo Pharmaceuticals   0.70   
0%
3.0%
MOLNMolecular Partners   0.17   
1.0%
0%
CELCCelcuity LLC   0.39   
1.0%
0%
PEPGPepGen   0.98   
4.0%
0%
IMRXImmuneering Corp   1.88   
8.0%
0%
PHVSPharvaris   2.06   
9.0%
0%
MLYSMineralys Therapeutics,   2.59   
11.0%
0%
ELVNEnliven Therapeutics   4.05   
18.0%
0%

Complementary Tools for Oric Stock analysis

When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance